BPC-157 and TB-500 healing claims: what the studies say

What did @therestoreclinic actually say?

The creator covered Sermorelin, a growth hormone releasing peptide, and answered a viewer question about dosing, frequency, and whether cycling is necessary. They put the typical dose at "100 and 300 micrograms at night," administered via subcutaneous injection on an empty stomach before bed. They said patients need "minimally at least three to six months" to notice any therapeutic benefit, and that while cycling is not strictly required, some patients develop "tachyphylaxis" with prolonged use, meaning the peptide stops working for them. They also grouped Sermorelin with Ipamorelin and CJC-1295 as interchangeable growth hormone secretagogues, which is worth examining more carefully.

Does the science back this up?

On the broad strokes, yes, with some important caveats. The nocturnal dosing rationale is sound. Growth hormone is secreted in pulses, with the largest pulse occurring during slow-wave sleep. Research supports timing secretagogue administration to coincide with this window. A study by Corpas et al. (1993, Journal of Clinical Endocrinology and Metabolism) confirmed Sermorelin's ability to amplify endogenous GH pulses in older adults when dosed appropriately. The empty stomach guidance also has a physiological basis: somatostatin, which blunts GH release, is elevated postprandially, so fasted administration reduces that suppression. The three-to-six month timeline for noticeable effects is consistent with how slowly GH-mediated changes, particularly in body composition and recovery, accumulate. Where the evidence gets thinner is on tachyphylaxis. The creator is right that it happens in a subset of patients, but the mechanism and prevalence in outpatient peptide therapy settings are not well characterized in peer-reviewed literature.

What did they get wrong (or right)?

They got the fundamentals right. Nocturnal subcutaneous injection, fasted state, realistic timelines, and an honest acknowledgment that cycling may not be necessary for everyone are all defensible positions. Giving credit where it is due: most creators in this space wildly oversell timelines and skip the nuance on tachyphylaxis entirely.

The grouping of Sermorelin, Ipamorelin, and CJC-1295 as interchangeable is where things get loose. These peptides work through different receptor pathways. Sermorelin and CJC-1295 are GHRH analogs. Ipamorelin is a ghrelin mimetic acting on the GHSR receptor. Combining them produces a synergistic effect that is meaningfully different from using either alone. Treating them as equivalent options understates that distinction. A review by Sigalos and Pastuszak (2018, Sexual Medicine Reviews) notes that combination protocols using GHRH analogs with ghrelin mimetics produce significantly greater GH release than either class alone. Calling them the same thing in a public-facing video flattens a distinction that matters clinically.

The 500 microgram outlier comment is worth flagging too. Framing higher doses as simply an outlier without noting that higher doses carry greater risk of side effects, including insulin resistance, fluid retention, and cortisol blunting, is an omission that matters for a general audience.

What should you actually know?

Sermorelin is a prescription peptide in the United States and is not legally available over the counter. It works by stimulating your pituitary gland to release growth hormone naturally, which is a different mechanism from injecting synthetic GH directly. That distinction matters because it means your body's own feedback loops remain active, which is generally considered safer than exogenous GH.

The tachyphylaxis point the creator raises is real but underexplored in published literature. Most of what practitioners know about it comes from clinical observation rather than controlled trials. If you are working with a provider on a secretagogue protocol, intermittent breaks, sometimes called pulsing schedules, are a reasonable precaution even without definitive data.

The three-to-six month window for results is honest and important. Anyone promising faster transformation from a GHRH peptide should be questioned. GH-mediated changes in body composition, sleep quality, and recovery are gradual. A study by Walker et al. (1990, Journal of Pediatric Endocrinology) tracking Sermorelin in GH-deficient patients showed measurable IGF-1 changes at three months, but functional outcomes took longer. Patience is not optional here.

Finally, anyone considering peptide therapy should have baseline labs including IGF-1, fasting glucose, and HbA1c. GH secretagogues can affect insulin sensitivity, and that needs monitoring, not just a starting dose.